Conferences & Events

Hemanext attends key medical congresses and conferences each year across various therapeutic areas.

If you are interested in reviewing an abstract or poster, please contact Hemanext Medical Information with your request.

Upcoming Conferences

AAST Annual Meeting

Dallas, TX, USA
16–19 Sept 2026

85th Annual Meeting of AAST & Clinical Congress of Acute Care Surgery.

ASCAT Conference 2026

London, UK
7–10 Oct 2026

21st Annual Sickle Cell & Thalassaemia Conference at Central Hall Westminster, London.

AABB Annual Meeting 2026

Atlanta, GA, USA
17–19 Oct 2026

Annual Meeting of the Association for the Advancement of Blood & Biotherapies.

Previous Conferences Attended

Western Trauma Association

Big Sky, MT, USA
1–6 Mar 2026

55th Western Trauma Association Annual Meeting at Big Sky Resort, Montana.

Conference website

AABB Annual Meeting 2025

San Diego, CA, USA
25–28 Oct 2025

ASCAT Conference 2025

London, UK
1–4 Oct 2025

Poster presentation by Delaporta P. et al: The αO2-PRBCThal trial on the use of Hemanext ONE for blood transfusion support transfusion-dependent thalassemia.

Presentation by Laurel Omert and James Hourani: Hypoxic Red Blood Cells: The Future for Patient Transfusions?

EHA2025 Congress

Milan, Italy
12–15 Jun 2025

Oral presentation by Dr. Håkon Reikvam, University of Bergen, Norway: Safety of Hypoxic Red Blood Cell Administration in Patients with Transfusion-Dependent Hematological Malignancies.

Read the abstract

ISBT Regional Congress

Milan, Italy
31 May–4 Jun 2025

Poster Presentation by Dr. Reinhard Henschler, University Hospital Leipzig, Germany: Hypoxic Storage of Leucodepleted PAGGS-M Erythrocyte Concentrates Results in Increased Quality, including Adenosine Triphosphate and 2,3 Diphosphoglycerate.

Abstract P244

Poster by Dr Vanessa Agostini et al: A validation study of the in vitro performance of hypoxic red blood cells for transfusion across centers in Europe.

Annual Conference on Shock

Boston, MA, USA
31 May–3 Jun 2025

Poster presentation by Stian K. Almeland, MD, PhD, Haukeland University Hospital/University of Bergen: First in Human Safety Evaluation of Hypoxic Red Blood Cell Transfusions to Acutely Bleeding Burn Patients.

EDQM Blood Conference

Strasbourg, France
14–15 Jan 2025

Oral presentation by Dr. Vanessa Agostini, San Martino Hospital, Genoa, Italy: Hypoxic red blood cells: an innovative blood product.

Abstract Page 35

AABB Annual Meeting 2024

Houston, TX, USA
19–22 Oct 2024

Poster presentations:

Dr. Laurel Omert: Transfusion of hypoxic red blood cells to hematologic malignancy patients and acutely bleeding burn patients.

Dr. Tatsuro Yoshida: Experimental Miniaturized O2/CO2-reduced storage device for cord blood and small animal models.

Dr. Tatsuro Yoshida: Optimizing ATP and 2,3-DPG of hypoxically stored whole blood.

ISBT International Congress

Barcelona, Spain
23–27 Jun 2024

Poster presentation by Dr. Vanessa Agostini, San Martino Hospital, Genoa, Italy: A multicentre European validation study of hypoxic red blood cells.

Abstract P214

By producing higher quality RBCs, the Hemanext ONE system has the potential to enable fewer and more effective transfusions for patients. I am truly excited by the possibility of bringing this improved red blood cell replacement therapy to populations in the U.S. that have been waiting for a transformative technology like this one.

Dr. Philip C. Spinella
Professor, Department of Surgery and Department of Critical Care Medicine at University of Pittsburgh

We value our partnership with Hemanext to enhance blood product quality and availability. Hemanext ONE has the potential to strengthen the resiliency of the blood supply, and this FDA authorization is a significant milestone to that end.

Ralph Vassallo, MD, FACP
Executive Vice President, Chief Medical and Scientific Officer of Vitalant

The Hemanext ONE system offers promise to improve the treatment landscape for patients burdened by transfusions and could be an essential step towards performing fewer and better transfusions. Having long championed Hemanext’s transformative initiatives, I eagerly anticipate witnessing the positive influence, right here in the United States, on the advancement of transfusion therapy quality.

Paul M. Ness, MD
Former Director, Division of Transfusion Medicine at Johns Hopkins University and board member of Hemanext

By deoxygenating red cells and maintaining them in their hypoxic state throughout storage, the resulting red cells experience less oxidative stress and oxidative damage, have improved metabolism, and are also more deformable leading to improved micro vascular profusion and less hemolysis.

Dr. Steven Spitalnik, MD
Co-Director of the Laboratory of Transfusion Biology, Colombia University

The preclinical data by Williams et al. show anaerobically stored RBCs achieve multiple clinically important functional resuscitation goals, with a smaller volume of fluid and the FDA benchmark of 24-hour RBC recovery. I look forward to the clinical trials in bleeding patients.

John Holcomb, MD, FACS
University of Alabama at Birmingham

I have had several patients who have received Hemanext hypoxic blood, and several of the patients have personally said thanks for having been given the opportunity and also that they have felt better after transfusion with hypoxic blood compared to conventional transfusion. One must of course be careful not to attach too much importance to such observations, but I would still like to mention that there has been a remarkable tendency towards this.

Håkon Reikvam, MD, PhD
Professor, Department of Clinical Science, University of Bergen, Norway

CONTACT US  |  TERMS OF USE

PRIVACY & COOKIES POLICY

This website may contain information on products or uses of those products that are not authorized in all countries or regions. Hemanext ONE has been granted marketing authorization for commercial distribution via the De Novo process by the U.S. Food & Drug Administration. In Europe Hemanext ONE is CE marked which allows the medical device to be placed in the market in the EEA. Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Hemanext, Hemanext ONE, and the logos are registered trademarks of Hemanext, Inc. © 2026 Hemanext, Inc. All rights reserved.

Contact Us